Latest Peplin news



Form 10-Q quarterly report read more

Peplin Results for the Quarter Ended 31 December 2008 read more


Positive results for Peplin's Phase IIb AK Trial read more


Peplin completes enrolment for its first phase III AK clinical trial read more


Form 10-Q - Quarterly Report read more

Registration statement including financial report read more

API Manufacturing

Peplin owns and operates a GMP licensed, commercial-scale manufacturing facility located in Southport, Queensland, Australia for API production of our proprietary, lead compound PEP005 (ingenol mebutate), a well characterized and purified single molecular entity sourced from a rapidly growing plant called Euphorbia peplus. The entire production process involves cultivation, post-harvest processing, GMP extraction, purification and formulation of PEP005 using strict quality standards for use in clinical trials.

Various contractors based in southeast Queensland and internationally support these activities.